300 related articles for article (PubMed ID: 19147081)
1. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
Pulsipher MA; Bader P; Klingebiel T; Cooper LJ
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):62-71. PubMed ID: 19147081
[TBL] [Abstract][Full Text] [Related]
2. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
3. Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.
Thiede Ch; Lutterbeck K; Oelschlägel U; Kiehl M; Steudel Ch; Platzbecker U; Brendel C; Fauser AA; Neubauer A; Ehninger G; Bornhäuser M
Ann Hematol; 2002; 81 Suppl 2():S27-8. PubMed ID: 12611065
[TBL] [Abstract][Full Text] [Related]
4. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
5. Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation.
Spinelli O; Giussani U; Borleri G; Lazzari M; Michelato A; Dotti G; Barbui T; Rambaldi A
Haematologica; 2000 Nov; 85(11):1153-7. PubMed ID: 11064467
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?
Schilham MW; Balduzzi A; Bader P;
Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S49-52. PubMed ID: 15812531
[TBL] [Abstract][Full Text] [Related]
7. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
8. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
Bader P; Kreyenberg H; Hoelle W; Dueckers G; Handgretinger R; Lang P; Kremens B; Dilloo D; Sykora KW; Schrappe M; Niemeyer C; Von Stackelberg A; Gruhn B; Henze G; Greil J; Niethammer D; Dietz K; Beck JF; Klingebiel T
J Clin Oncol; 2004 May; 22(9):1696-705. PubMed ID: 15117992
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
11. [The clinical significance of interphase fluorescence in situ hybridization monitoring chimeric status after sex-mismatched allogeneic hematopoietic stem cell transplantation for leukemia].
Liu Q; Song L; Zhang Y; Wei Y; Xu D; Sun J; Liu X; Xu B; Meng F; Zhou S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Apr; 22(2):212-5. PubMed ID: 15793790
[TBL] [Abstract][Full Text] [Related]
12. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
[TBL] [Abstract][Full Text] [Related]
13. New approaches to acute lymphoblastic leukemia in adults: where do we go?
Hoelzer D; Gökbuget N
Semin Oncol; 2000 Oct; 27(5):540-59. PubMed ID: 11049022
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
15. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Shi HX; Han W; Zhan XH; Wang Y; Zhao T; Huang XJ
Chin Med J (Engl); 2011 Jan; 124(2):246-52. PubMed ID: 21362375
[TBL] [Abstract][Full Text] [Related]
16. Influence of transplantation regimen on prognostic significance of high-level minimal residual disease before allogeneic stem cell transplantation in children with ALL.
Schneider M; Hettinger K; Matthes-Martin S; Konrad M; Peters C; Gadner H; Panzer-Grümayer ER
Bone Marrow Transplant; 2001 Dec; 28(11):1087-9. PubMed ID: 11781621
[TBL] [Abstract][Full Text] [Related]
17. The value of monitoring minimal residual disease in the patients with donor lymphocyte infusion as intervention of relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Ma X; Wu D; Sun A; Qiu H; Fu Z; Wu X; Chen S; Mohty M
Am J Hematol; 2010 Feb; 85(2):141-2. PubMed ID: 20029991
[No Abstract] [Full Text] [Related]
18. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective.
Bader P; Kreyenberg H; Hoelle W; Dueckers G; Kremens B; Dilloo D; Sykora KW; Niemeyer C; Reinhardt D; Vormoor J; Gruhn B; Lang P; Greil J; Handgretinger R; Niethammer D; Klingebiel T; Beck JF
Bone Marrow Transplant; 2004 Apr; 33(8):815-21. PubMed ID: 14990984
[TBL] [Abstract][Full Text] [Related]
19. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review.
Hahn T; Wall D; Camitta B; Davies S; Dillon H; Gaynon P; Larson RA; Parsons S; Seidenfeld J; Weisdorf D; McCarthy PL
Biol Blood Marrow Transplant; 2005 Nov; 11(11):823-61. PubMed ID: 16275588
[TBL] [Abstract][Full Text] [Related]
20. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.
Lankester AC; Bierings MB; van Wering ER; Wijkhuijs AJ; de Weger RA; Wijnen JT; Vossen JM; Versluys B; Egeler RM; van Tol MJ; Putter H; Révész T; van Dongen JJ; van der Velden VH; Schilham MW
Leukemia; 2010 Aug; 24(8):1462-9. PubMed ID: 20535148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]